US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Anti-Pandemic Concept

1,327.58

-9.1315-0.68%

Number of Gainers:5

Number of Losers:15

Number of Flat:- -

PE:- -

High:1,343.21

Open:1,342.69

Low:1,326.57

Close:1,336.71

Loading ...

Gilead Sciences Inc - Stockholders Reject Dei Practices Risk Report Proposal for Contractors - SEC Filing

THOMSON REUTERS

Gilead Sciences Inc. Conducted Annual Stockholder Meeting

Corvus Pharmaceuticals Reports Q1 2025 Results: Net Income Surges to $15.2M, Driven by $25.1M Gain from Warrant Liability Adjustment

Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2025 Financial Results

THOMSON REUTERS

Corvus Pharmaceuticals Inc Q1 Shr View $-0.12 -- Lseg Ibes Data

THOMSON REUTERS

Corvus Pharmaceuticals Inc: Qtrly Loss per Share $0.13

THOMSON REUTERS

Corvus Pharmaceuticals Announces Data From Cohorts 1-3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

THOMSON REUTERS

Corvus Pharmaceuticals Inc - Data Shows Favorable Safety and Efficacy Profile in Cohort 3

THOMSON REUTERS

Corvus Pharmaceuticals Inc - Soquelitinib Well Tolerated With No Dose Limiting Toxicities

THOMSON REUTERS

Port of Long Beach Fears 'Covid-19 Moment' Without Trade Deals -- WSJ

COVID Vaccine Maker Novavax Stock Soars 16% - Here's Why

Mixed options sentiment in Moderna (MRNA), with shares up $0.33 (+1.35%) near $24.39.

Why This Shrinking Covid-19 Vaccine Stock Jumped 30% -- Barrons.com

Gilead put volume heavy and directionally bearish

Novavax Shares Rise After Swinging to Q1 Profit

MT Newswires Live

Refile-Novavax Shares Rise 20% After Co Swings to Q1 Profit (Removes Extraneous Word)

THOMSON REUTERS

Novavax Shares Rise 20% Premarket After Co Swings to Q1 Profit

THOMSON REUTERS

Alpha Pro Tech Ltd: New Tariffs on India May Negatively Affect Our Margins on Products We Produce There

THOMSON REUTERS

Alpha Pro Tech, Ltd. Announces First Quarter 2025 Financial Results

THOMSON REUTERS

Alpha Pro Tech Q1 EPS USD 0.06

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BK4568/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4568","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4568\",,,,,undefined,":{"symbol":"BK4568","market":"US","secType":"PLATE","nameCN":"Anti-Pandemic Concept","latestPrice":1327.5806,"timestamp":1746820799999,"preClose":1336.712,"halted":0,"volume":113582454,"delay":0,"changeRate":-0.006831,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Market Closed","change":-9.13147,"latestTime":"05-09 16:00:00 EDT","open":1342.69,"high":1343.2052,"low":1326.5701,"amount":4653162209.902576,"amplitude":0.012445,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1747036800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":3.565313,"peRate":21.186942,"turnoverRate":0.007317,"increases":5,"decrements":15,"flats":0,"marketCap":1093969830401.5,"floatMarketCap":1075897192963},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4568\",,,,,undefined,":{"symbol":"BK4568","high":1343.2052,"amplitude":0.012445,"preClose":1336.712,"low":1326.5701,"pbRate":"3.565313","latestPrice":1327.5806,"volume":113582454,"delay":0,"open":1342.69,"prevYearClose":1274.8187,"prevWeekClose":1375.2667,"prevMonthClose":1374.5028,"prevQuarterClose":1427.887,"fiveDayClose":1375.2667,"twentyDayClose":1281.7616,"sixtyDayClose":1380.7908,"secType":"PLATE","market":"US","turnoverRate":0.007317,"peRate":21.186942,"marketCap":1093969830401.5,"floatMarketCap":1075897192963,"timestamp":1746820799999,"nameCN":"Anti-Pandemic Concept"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4568\",,,,undefined,":{"bkCode":"BK4568","up":5,"down":15,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4568\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2534719332","title":"Gilead Sciences Inc - Stockholders Reject Dei Practices Risk Report Proposal for Contractors - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2534719332","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534719332?lang=en_us&edition=fundamental","pubTime":"2025-05-09 06:13","pubTimestamp":1746742433,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250508:nFWN3RG4BE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1066051498.USD","BK4532","LU1674673428.USD","IE00BKVL7J92.USD","LU1839511570.USD","LU1430594728.SGD","BK4585","LU1585245621.USD","LU0109394709.USD","LU2089984988.USD","LU2468319806.SGD","IE00BZ1G4Q59.USD","BK4139","BK4588","IE00B19Z3B42.SGD","IE00B7SZLL34.SGD","IE00B19Z3581.USD","LU2087621335.USD","BK4550","BK4578","IE0002270589.USD","LU0320765992.SGD","LU1066053197.SGD","BK4566","LU1571399168.USD","LU0234570918.USD","LU1778281490.HKD","IE00BSNM7G36.USD","LU0289739699.SGD","BK4568","LU1674673691.USD","BK4583","GILD","LU0889565916.HKD","IE00B3T34201.USD","LU0058720904.USD"],"gpt_icon":0},{"id":"2534953411","title":"Gilead Sciences Inc. Conducted Annual Stockholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2534953411","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534953411?lang=en_us&edition=fundamental","pubTime":"2025-05-09 06:06","pubTimestamp":1746741995,"startTime":"0","endTime":"0","summary":"Gilead Sciences Inc. held its annual meeting of stockholders on May 7, 2025. Stockholders elected nine directors. A proposal for an independent Board Chair policy was not approved. A proposal requesting a comprehensive human rights policy and due diligence process was not approved. A proposal requesting a report on the risks of DEI practices for contractors was not approved. A proposal requesting the CEO pay ratio factor be included in executive compensation programs was not approved. The selection of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gilead Sciences Inc. published the original content used to ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250508:nNDL6fk5vT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1839511570.USD","IE00B3T34201.USD","BK4585","IE00B7SZLL34.SGD","BK4139","BK4578","LU0058720904.USD","LU1585245621.USD","IE00BZ1G4Q59.USD","LU1571399168.USD","LU0109394709.USD","BK4568","LU1066051498.USD","LU2468319806.SGD","IE00BKVL7J92.USD","LU1430594728.SGD","LU0889565916.HKD","LU1674673428.USD","BK4550","BK4583","BK4532","LU1674673691.USD","LU2089984988.USD","BK4566","LU2087621335.USD","LU1778281490.HKD","LU0289739699.SGD","LU0320765992.SGD","IE00BSNM7G36.USD","LU1066053197.SGD","IE00B19Z3B42.SGD","IE0002270589.USD","LU0234570918.USD","GILD","IE00B19Z3581.USD","BK4588"],"gpt_icon":0},{"id":"2534316645","title":"Corvus Pharmaceuticals Reports Q1 2025 Results: Net Income Surges to $15.2M, Driven by $25.1M Gain from Warrant Liability Adjustment","url":"https://stock-news.laohu8.com/highlight/detail?id=2534316645","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534316645?lang=en_us&edition=fundamental","pubTime":"2025-05-09 04:03","pubTimestamp":1746734619,"startTime":"0","endTime":"0","summary":"Corvus Pharmaceuticals Reports Q1 2025 Results: Net Income Surges to $15.2M, Driven by $25.1M Gain from Warrant Liability Adjustment. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corvus Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 08, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250508:nNDL7qSM9k:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","BK4139","CRVS"],"gpt_icon":0},{"id":"2534216573","title":"Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2534216573","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534216573?lang=en_us&edition=fundamental","pubTime":"2025-05-09 04:02","pubTimestamp":1746734520,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250508:nTUA1YSQTN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CRVS","BK4139","BK4568"],"gpt_icon":0},{"id":"2534166820","title":"Corvus Pharmaceuticals Inc  Q1 Shr View $-0.12 -- Lseg Ibes Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2534166820","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534166820?lang=en_us&edition=fundamental","pubTime":"2025-05-09 04:02","pubTimestamp":1746734520,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250508:nTUA1YSQTN:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4568","CRVS","BK4139"],"gpt_icon":0},{"id":"2534165001","title":"Corvus Pharmaceuticals Inc: Qtrly Loss per Share $0.13","url":"https://stock-news.laohu8.com/highlight/detail?id=2534165001","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534165001?lang=en_us&edition=fundamental","pubTime":"2025-05-09 04:02","pubTimestamp":1746734520,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250508:nTUA1YSQTN:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CRVS","BK4568","BK4139"],"gpt_icon":0},{"id":"2534654171","title":"Corvus Pharmaceuticals Announces Data From Cohorts 1-3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2534654171","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534654171?lang=en_us&edition=fundamental","pubTime":"2025-05-09 04:01","pubTimestamp":1746734460,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250508:nTUA3LGFQG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CRVS","BK4568","BK4139"],"gpt_icon":0},{"id":"2534316546","title":"Corvus Pharmaceuticals Inc - Data Shows Favorable Safety and Efficacy Profile in Cohort 3","url":"https://stock-news.laohu8.com/highlight/detail?id=2534316546","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534316546?lang=en_us&edition=fundamental","pubTime":"2025-05-09 04:01","pubTimestamp":1746734460,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250508:nTUA3LGFQG:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4568","CRVS"],"gpt_icon":0},{"id":"2534165217","title":"Corvus Pharmaceuticals Inc - Soquelitinib Well Tolerated With No Dose Limiting Toxicities","url":"https://stock-news.laohu8.com/highlight/detail?id=2534165217","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534165217?lang=en_us&edition=fundamental","pubTime":"2025-05-09 04:01","pubTimestamp":1746734460,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250508:nTUA3LGFQG:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4568","BK4139","CRVS"],"gpt_icon":0},{"id":"2534684401","title":"Port of Long Beach Fears 'Covid-19 Moment' Without Trade Deals -- WSJ","url":"https://stock-news.laohu8.com/highlight/detail?id=2534684401","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534684401?lang=en_us&edition=fundamental","pubTime":"2025-05-09 03:05","pubTimestamp":1746731100,"startTime":"0","endTime":"0","summary":"The Port of Long Beach could face a situation similar to one it encountered during the pandemic if trade deals don't happen, its leader says.\"It's a Covid-19 moment in regards to cargo movement,\" said Mario Cordero, CEO of the California port, in an interview on CNBC. Cordero was responding to a question about the worst case scenario in the coming months. \"The concerns are real.\". Cordero said there is \"light at the end of the tunnel,\" but noted that it could take at least a month after major deals are struck for the regular flow of cargo to level off.This item is part of a Wall Street Journal live coverage event. The full stream can be found by searching P/WSJL .","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4551","BK4535","BK4588","BNTX","BK4548","BK4568","BK4585"],"gpt_icon":0},{"id":"2534154014","title":"COVID Vaccine Maker Novavax Stock Soars 16% - Here's Why","url":"https://stock-news.laohu8.com/highlight/detail?id=2534154014","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534154014?lang=en_us&edition=fundamental","pubTime":"2025-05-09 01:31","pubTimestamp":1746725514,"startTime":"0","endTime":"0","summary":"Novavax posts $667 million in Q1 2025 revenue and $2.93 EPS, boosted by Sanofi payments and APA terminations; full-year outlook raised above expectations.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/25/05/45295534/novavax-reports-q1-profit-as-revenue-surges-to-over-600-million-and-lower-costs-raises-2025-forecasts","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BFXG1179.USD","BK4213","BK4585","NVAX","BK4568","LU0256331488.USD","BK4547","BK4007","BK4139","APA","SNY","BK4588"],"gpt_icon":0},{"id":"2533513072","title":"Mixed options sentiment in Moderna (MRNA), with shares up $0.33 (+1.35%) near $24.39.","url":"https://stock-news.laohu8.com/highlight/detail?id=2533513072","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533513072?lang=en_us&edition=fundamental","pubTime":"2025-05-08 23:20","pubTimestamp":1746717645,"startTime":"0","endTime":"0","summary":"Options volume is more than double the daily average, with 81k contracts traded and calls leading puts for a put/call ratio of 0.07, compared to a ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/mixed-options-sentiment-in-moderna-mrna-with-shares-up-0-33-1-35-near-24-39?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/mixed-options-sentiment-in-moderna-mrna-with-shares-up-0-33-1-35-near-24-39?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4533","BK4568","BK4585","BK4588","BK4139","BK4501","BK4548","BK4551","MRNA","BK4532","BK4534"],"gpt_icon":0},{"id":"2533370211","title":"Why This Shrinking Covid-19 Vaccine Stock Jumped 30% -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2533370211","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533370211?lang=en_us&edition=fundamental","pubTime":"2025-05-08 23:12","pubTimestamp":1746717120,"startTime":"0","endTime":"0","summary":"Vaccine maker Novavax stock jumped double digits on Thursday after the company reported its quarterly sales had more than fivefold.Shares rose as much 30% at the opening bell, but later pared backs its gains. In midmorning trading the stock was up 17% at $6.93.First-quarter earnings were $2.93 a share on sales of $667 million. The numbers trounced Wall Street's expectation of a loss of 42 cents a share on sales of $92 million, according to a small group of analysts surveyed by FactSet.Novavax also said it is in discussions with the Food and Drug Administration about full approval for its Covid-19 vaccine, Nuvaxovid, which has only the emergency approval it received in the pandemic. The FDA delayed full approval in April.The earnings beat was primarily due to a $603 million revenue post related to the termination of two advanced purchase agreements. Licensing and royalties revenue related to its partnership with European pharma giant Sanofi were also higher than last year.Novavax, which","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4551","BK4535","BK4548","BK4568","IE00BFXG1179.USD","BK4585","NVAX","BK4588","BK4547","BK4139","BK4007","SNY","BNTX"],"gpt_icon":0},{"id":"2533132699","title":"Gilead put volume heavy and directionally bearish","url":"https://stock-news.laohu8.com/highlight/detail?id=2533132699","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533132699?lang=en_us&edition=fundamental","pubTime":"2025-05-08 22:40","pubTimestamp":1746715228,"startTime":"0","endTime":"0","summary":"Bearish flow noted in Gilead (GILD) with 3,289 puts trading, or 2x expected. Most active are Jan-26 90 puts and Jun-25 90 puts, with total volume i...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/gilead-put-volume-heavy-and-directionally-bearish-6?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/gilead-put-volume-heavy-and-directionally-bearish-6?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4532","LU0289739699.SGD","LU2089984988.USD","IE00B7SZLL34.SGD","BK4139","LU1066053197.SGD","LU1430594728.SGD","LU1674673691.USD","BK4568","IE00BKVL7J92.USD","IE00BSNM7G36.USD","LU1839511570.USD","BK4583","IE00B19Z3B42.SGD","LU1778281490.HKD","LU1571399168.USD","LU0889565916.HKD","LU1585245621.USD","BK4585","LU0234570918.USD","IE00BZ1G4Q59.USD","IE00B3T34201.USD","IE0002270589.USD","LU1066051498.USD","LU0320765992.SGD","LU2087621335.USD","BK4578","BK4588","BK4566","LU0109394709.USD","GILD","IE00B19Z3581.USD","BK4550","LU1674673428.USD","LU0058720904.USD","LU2468319806.SGD"],"gpt_icon":0},{"id":"2533347721","title":"Novavax Shares Rise After Swinging to Q1 Profit","url":"https://stock-news.laohu8.com/highlight/detail?id=2533347721","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533347721?lang=en_us&edition=fundamental","pubTime":"2025-05-08 22:20","pubTimestamp":1746714018,"startTime":"0","endTime":"0","summary":"Novavax  shares were up over 16% in recent Thursday trading after the company reported it swung to Q1 net income of $2.93 per diluted share from a net loss of $1.05 a year earlier.Three analysts polled by FactSet expected a loss of $0.42.Revenue for the quarter ended March 31 was $666.7 million, up from $93.9 million a year earlier.Two analysts surveyed by FactSet expected $91.7 million.The drugmaker said it expects 2025 adjusted total revenue of between $975 million and $1.03 billion.Price: 6.93, Change: +0.98, Percent Change: +16.47","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","BK4568","BK4547","BK4588","NVAX","BK4585"],"gpt_icon":0},{"id":"2533351981","title":"Refile-Novavax Shares Rise 20% After Co Swings to Q1 Profit (Removes Extraneous Word)","url":"https://stock-news.laohu8.com/highlight/detail?id=2533351981","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533351981?lang=en_us&edition=fundamental","pubTime":"2025-05-08 21:38","pubTimestamp":1746711536,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250508:nL8N3RG252:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4588","BK4568","BK4585","BK4547","NVAX"],"gpt_icon":0},{"id":"2533135506","title":"Novavax Shares Rise 20% Premarket After Co Swings to Q1 Profit","url":"https://stock-news.laohu8.com/highlight/detail?id=2533135506","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533135506?lang=en_us&edition=fundamental","pubTime":"2025-05-08 21:32","pubTimestamp":1746711164,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250508:nFWN3RG49M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4568","BK4588","NVAX","BK4139","BK4585","BK4547"],"gpt_icon":0},{"id":"2533388811","title":"Alpha Pro Tech Ltd: New Tariffs on India May Negatively Affect Our Margins on Products We Produce There","url":"https://stock-news.laohu8.com/highlight/detail?id=2533388811","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533388811?lang=en_us&edition=fundamental","pubTime":"2025-05-08 21:00","pubTimestamp":1746709215,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250508:nTUA3B9D13:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4568","BK4086","APT"],"gpt_icon":0},{"id":"2533047180","title":"Alpha Pro Tech, Ltd. Announces First Quarter 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2533047180","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533047180?lang=en_us&edition=fundamental","pubTime":"2025-05-08 21:00","pubTimestamp":1746709215,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250508:nTUA3B9D13:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["APT","BK4086","BK4568"],"gpt_icon":0},{"id":"2533800001","title":"Alpha Pro Tech Q1 EPS USD 0.06","url":"https://stock-news.laohu8.com/highlight/detail?id=2533800001","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533800001?lang=en_us&edition=fundamental","pubTime":"2025-05-08 21:00","pubTimestamp":1746709215,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250508:nPLX0E9EB1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["APT","BK4086","BK4568"],"gpt_icon":0}],"pageSize":20,"totalPage":17,"pageCount":2,"totalSize":328,"code":"91000000","status":"200"}]}}